Preliminary results of retrospective analysis Atezolizumab and Bevacizumab in first-line therapy of advanced HCC
Introduction. HCC is a challenge for clinical oncology. 1-year mortality for advanced HCC accounts for 66% in theRussian Federation. The results obtained in the combined Atezolizumab and Bevacizumab therapy in the advanced HCC cases are reported.Objective. To assess efficacy and safety of anti-VEGF/...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Remedium Group LLC
2021-06-01
|
| Series: | Медицинский совет |
| Subjects: | |
| Online Access: | https://www.med-sovet.pro/jour/article/view/6206 |
| _version_ | 1797841687365550080 |
|---|---|
| author | I. А. Dzhanyan М. V. Natrusova V. V. Breder |
| author_facet | I. А. Dzhanyan М. V. Natrusova V. V. Breder |
| author_sort | I. А. Dzhanyan |
| collection | DOAJ |
| description | Introduction. HCC is a challenge for clinical oncology. 1-year mortality for advanced HCC accounts for 66% in theRussian Federation. The results obtained in the combined Atezolizumab and Bevacizumab therapy in the advanced HCC cases are reported.Objective. To assess efficacy and safety of anti-VEGF/PD-L1 Atezolizumab plus Bevacizumab therapy in 20 unresectable HCC patients.Materials and methods. This analyses carried out in Blokhin National Cancer Research Centre included 20 patients with unresectable HCC treated with the first-line Atezolizumab (1200 mg) and Bevacizumab (15 mg/kg) once every 21 days, 11 patients participated into the global open-label phase 3 trial IMbrave150 23,24 (NCT03434379 / YO40245; Sponsor of study F. Hoffmann-La Roche, Ltd). The therapy was discontinued in cases of tumor progression or intolerant toxicity. The efficacy was evaluated according to RECICT 1.1 criteria. The results were analyzed and visualized on the basis of statistical calculations R 3.6.3 (R Foundation for Statistical Computing, Vienna, Austria). Descriptive statistics for quantitative variables are presented as mean (standard devia[1]tion) and median (lower and upper quartiles), for categorial variables as absolute number of observations (%). To compare quan[1]titative variables (AFP level) in progress Wilcoxon test was used. The differences were considered statistically significant with p < 0.05. Overall survival (OS) and progression-free survival (PFS) data were evaluated according to Kaplan-Meier methodology.Results and discussion. Median follow up was 9.3 months (quartile 1–3: 6.0–14.4) for 20 patients. Median progression free sur[1]vival was 14.9 months (lower bound, 95% CI, 9.0 months, upper bound NA). 12–month progression-free survival rate from the fixed date of the initial therapy was 56.2% (95% CI: 34.4–91.8%). One-year survival for 20 patients from the fixed date of the initial therapy was 70.0% (95% CI: 49–100). Treatment resulted in objective response (partial regression) in 3 (15%) pts, stable disease in 13 (65.0%) and progression in 4 (20.0%), patients. 35% of patients experienced Gr 3–4 adverse events with Gr3–4 arterial hypertension was the most common one in 20%. In 1 case esophageal varices hemorrhage Gr3 took place.Conclusion. Atezolizumab and Bevacizumab seems to be highly efficient in advanced HCC. |
| first_indexed | 2024-04-09T16:35:21Z |
| format | Article |
| id | doaj.art-4765a8f39d4247c4b9da8728757063e0 |
| institution | Directory Open Access Journal |
| issn | 2079-701X 2658-5790 |
| language | Russian |
| last_indexed | 2024-04-09T16:35:21Z |
| publishDate | 2021-06-01 |
| publisher | Remedium Group LLC |
| record_format | Article |
| series | Медицинский совет |
| spelling | doaj.art-4765a8f39d4247c4b9da8728757063e02023-04-23T06:56:56ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902021-06-0104S81510.21518/2079-701X-2021-4S-8-155625Preliminary results of retrospective analysis Atezolizumab and Bevacizumab in first-line therapy of advanced HCCI. А. Dzhanyan0М. V. Natrusova1V. V. Breder2Blokhin National Medical Research Center of OncologyLomonosov Moscow State UniversityBlokhin National Medical Research Center of OncologyIntroduction. HCC is a challenge for clinical oncology. 1-year mortality for advanced HCC accounts for 66% in theRussian Federation. The results obtained in the combined Atezolizumab and Bevacizumab therapy in the advanced HCC cases are reported.Objective. To assess efficacy and safety of anti-VEGF/PD-L1 Atezolizumab plus Bevacizumab therapy in 20 unresectable HCC patients.Materials and methods. This analyses carried out in Blokhin National Cancer Research Centre included 20 patients with unresectable HCC treated with the first-line Atezolizumab (1200 mg) and Bevacizumab (15 mg/kg) once every 21 days, 11 patients participated into the global open-label phase 3 trial IMbrave150 23,24 (NCT03434379 / YO40245; Sponsor of study F. Hoffmann-La Roche, Ltd). The therapy was discontinued in cases of tumor progression or intolerant toxicity. The efficacy was evaluated according to RECICT 1.1 criteria. The results were analyzed and visualized on the basis of statistical calculations R 3.6.3 (R Foundation for Statistical Computing, Vienna, Austria). Descriptive statistics for quantitative variables are presented as mean (standard devia[1]tion) and median (lower and upper quartiles), for categorial variables as absolute number of observations (%). To compare quan[1]titative variables (AFP level) in progress Wilcoxon test was used. The differences were considered statistically significant with p < 0.05. Overall survival (OS) and progression-free survival (PFS) data were evaluated according to Kaplan-Meier methodology.Results and discussion. Median follow up was 9.3 months (quartile 1–3: 6.0–14.4) for 20 patients. Median progression free sur[1]vival was 14.9 months (lower bound, 95% CI, 9.0 months, upper bound NA). 12–month progression-free survival rate from the fixed date of the initial therapy was 56.2% (95% CI: 34.4–91.8%). One-year survival for 20 patients from the fixed date of the initial therapy was 70.0% (95% CI: 49–100). Treatment resulted in objective response (partial regression) in 3 (15%) pts, stable disease in 13 (65.0%) and progression in 4 (20.0%), patients. 35% of patients experienced Gr 3–4 adverse events with Gr3–4 arterial hypertension was the most common one in 20%. In 1 case esophageal varices hemorrhage Gr3 took place.Conclusion. Atezolizumab and Bevacizumab seems to be highly efficient in advanced HCC.https://www.med-sovet.pro/jour/article/view/6206hccimmunotherapyatezolizumabbevacizumabanti-vegf/pd-l1cirrhosis |
| spellingShingle | I. А. Dzhanyan М. V. Natrusova V. V. Breder Preliminary results of retrospective analysis Atezolizumab and Bevacizumab in first-line therapy of advanced HCC Медицинский совет hcc immunotherapy atezolizumab bevacizumab anti-vegf/pd-l1 cirrhosis |
| title | Preliminary results of retrospective analysis Atezolizumab and Bevacizumab in first-line therapy of advanced HCC |
| title_full | Preliminary results of retrospective analysis Atezolizumab and Bevacizumab in first-line therapy of advanced HCC |
| title_fullStr | Preliminary results of retrospective analysis Atezolizumab and Bevacizumab in first-line therapy of advanced HCC |
| title_full_unstemmed | Preliminary results of retrospective analysis Atezolizumab and Bevacizumab in first-line therapy of advanced HCC |
| title_short | Preliminary results of retrospective analysis Atezolizumab and Bevacizumab in first-line therapy of advanced HCC |
| title_sort | preliminary results of retrospective analysis atezolizumab and bevacizumab in first line therapy of advanced hcc |
| topic | hcc immunotherapy atezolizumab bevacizumab anti-vegf/pd-l1 cirrhosis |
| url | https://www.med-sovet.pro/jour/article/view/6206 |
| work_keys_str_mv | AT iadzhanyan preliminaryresultsofretrospectiveanalysisatezolizumabandbevacizumabinfirstlinetherapyofadvancedhcc AT mvnatrusova preliminaryresultsofretrospectiveanalysisatezolizumabandbevacizumabinfirstlinetherapyofadvancedhcc AT vvbreder preliminaryresultsofretrospectiveanalysisatezolizumabandbevacizumabinfirstlinetherapyofadvancedhcc |